Welcome!

News Feed Item

PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria

LONDON, Feb. 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria

PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria

Summary

Since their discovery almost a century ago, antibiotics have revolutionized the global healthcare industry by ushering in an era of significantly reduced morbidity and mortality associated with often-lethal bacterial infections. However, the increasing threat posed by multidrug-resistant (MDR) bacteria, in particular gram-negative organisms, has cast a shadow over these remarkable public health achievements. GlobalData's primary research indicates that this high level of unmet need has generated several opportunities for firms seeking access to the market in the US or 5EU. Public and private entities have also launched initiatives to make antibiotic R&D an attractive therapy area. GlobalData anticipates that a mixture of push, pull, and hybrid mechanisms will encourage progress through all stages of antibiotic development. Increased flexibility from the FDA and EMA is also expected to decrease barriers to entry for drugs targeting MDR gram-negative bacteria. GlobalData believes that a partnership approach, involving academia, small and medium enterprises, and Big Pharma, is the best strategy for companies hoping to leverage these incentives to gain access to the market.

Highlights

Key Questions Answered

- What are the main unmet needs associated with treating drug-resistant gram-negative bacterial infections?
- What opportunities can companies exploit to gain access to the US and 5EU markets?
- What incentive mechanisms and programs can companies leverage to fund their antibiotic R&D?
- How is the changing regulatory landscape at the FDA and EMA going to affect the review of antibiotics for MDR gram-negative bacterial infections?
- What advantages does the public-private partnership approach to antibiotic R&D have over the traditional business plan for antibiotics?

Key Findings

- The escalating need for therapies against MDR gram-negative bacteria has created opportunities that can be leveraged to enter the marketplace in both the US and 5EU.
- Incentive initiatives, such as the Generating Antibiotics Incentives Now (GAIN) Act, are making antibiotics an attractive therapy area.
- The FDA and EMA have both expressed and demonstrated a willingness to increase their flexibility regarding clinical trial design and endpoints.
- The partnership approach to antibiotic R&D, which involves collaboration between academia, small and medium enterprises, and Big Pharma, is replacing the solo approach traditionally used by companies.

Scope

- Overview of incentive mechanisms and programs designed to encourage antibiotic R&D, current regulatory trends, and the role of academia, small and medium enterprises and Big Pharma in bringing next-generation antibiotics to market.
- Key topics covered include unmet needs, opportunities, and the emergence of public-private partnerships in the market for antibiotics targeting multidrug-resistant gram-negative bacteria.
- Analysis of the key industry drivers, restraints and challenges in the US and 5EU. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your market access strategy through a review of clinical and commercial unmet needs as well as regulatory trends related to gram-negative antibiotics.
- Develop business strategies by understanding the trends shaping and driving the gram-negative antibiotics market in the US and 5EU.
- Drive revenues by understanding the key trends and opportunities likely to impact the US and 5EU gram-negative antibiotics markets.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 11
3 Market Drivers and Barriers 12
3.1 Overview 12
3.2 Drivers 14
3.2.1 Driver: Increase in the Incidence of MDR Gram-Negative Bacterial Infections 14
3.2.2 Driver: Higher Pricing of Novel Antibiotics 15
3.2.3 Driver: A Rising Awareness of the Need for Novel Antibiotics 17
3.2.4 Driver: Economic Incentive Programs for Antibiotic Development 18
3.2.5 Driver: Regulatory Reform and Clinical Trial Redesign 19
3.2.6 Driver: Publically-Funded Resources or Partnerships (PPPs) 21
3.2.7 Driver: Improved Diagnostic Tools 22
3.2.8 Driver: Efforts to Decrease Overall Healthcare Costs 24
3.3 Barriers 25
3.3.1 Barrier: Low ROI Compared with Other Therapy Areas 25
3.3.2 Barrier: Difficulty Developing Truly Novel Antibiotics 26
3.3.3 Barrier: Antibiotic Stewardship 28
3.3.4 Barrier: Limited Awareness of the Threat Posed by Drug-Resistant Bacteria 29
3.3.5 Barrier: Convoluted, Shifting Regulatory Requirements 31
3.3.6 Barrier: Regulatory Bureaucracy 32
3.3.7 Barrier: Cost-Conscious Governments 34
3.3.8 Barrier: Movement Towards Preventative Care 35
3.3.9 Barrier: Competition from Cheap, Generally-Effective Generics 36
4 Unmet Needs Assessment and Opportunity Analysis 38
4.1 Unmet Needs Overview 38
4.1.1 Unmet Need: Antibiotics that Treat MDR Gram-Negative Infections 40
4.1.2 Unmet Need: Antibiotics with Novel Mechanisms of Action Targeted at Specific Pathogens 41
4.1.3 Unmet Need: Accurate, Rapid, and Inexpensive Diagnostic Tools 43
4.1.4 Unmet Need: Increase Awareness of the Threat Posed by Antibiotic Resistance 45
4.1.5 Unmet Need: Streamlined Treatment Guidelines or Global Approaches to Combat Resistance 47
4.2 Opportunities Overview 49
4.2.1 Opportunity: Screen Molecules in an Environment Similar to the Infection Site 51
4.2.2 Opportunity: Biologicals as Antibiotics 52
4.2.3 Opportunity: Leveraging Novel Diagnostics to Achieve and Maintain Commercial Success 54
4.2.4 Opportunity: Enhancing the Activity of Existing Antibiotics Against MDR Infections 55
4.2.5 Opportunity: Probiotics and Natural Flora 56
5 Incentives for Antibiotic Development 58
5.1 Overview 58
5.2 Push Incentives 61
5.2.1 Overview 61
5.2.2 Advantages 63
5.2.3 Disadvantages 63
5.3 Pull Incentives 65
5.3.1 Overview 65
5.3.2 Advantages 67
5.3.3 Disadvantages 67
5.4 Combination and Hybrid Incentives 69
5.4.1 Overview 69
5.4.2 Advantages 70
5.4.3 Disadvantages 71
6 Current Regulatory Trends 72
6.1 Overview of Regulatory Trends 72
6.1.1 Increased Pragmatism Regarding Clinical Trial Endpoints 76
6.1.2 Recognition of Preclinical-Clinical Activity Correlation (PK/PD) 78
6.1.3 Escalating Value of Microbiological Diagnostics 79
6.1.4 More Practical Risk-Benefit Assessment 80
6.1.5 Establishing an FDA-EMA Regulatory Accord for Antibiotics 82
7 The Need for an Alternative Approach to Antibiotic R&D 84
7.1 Overview 84
7.1.1 The Traditional Approach 84
7.1.2 The Partnership Approach 86
7.2 Stakeholders 89
7.2.1 The Role of Big Pharma 89
7.2.2 The Role of Academia and SMEs 91
7.2.3 The Role of Government 94
8 Appendix 97
8.1 Bibliography 97
8.2 Abbreviations 104
8.3 Physicians and Specialists Included in this Study 107
8.4 About the Authors 111
8.4.1 Authors 111
8.4.2 Reviewer 112
8.4.3 Global Head of Healthcare 112
8.5 About GlobalData 113
8.6 Disclaimer 113

List of Tables

Table 1: MDR Gram-Negative Infections – Drivers and Barriers, 2013 13
Table 2: 6MM Unmet Needs – Current Level of Attainment 39
Table 3: Push Incentives Overview 61
Table 4: Pull Incentives Overview 66
Table 5: Hybrid Incentives Overview 69
Table 6: Role of Big Pharma in Antibiotic R&D 90
Table 7: Role of Academic and SME Entities in Antibiotic R&D 92
Table 8: Role of Government Agencies in Antibiotic R&D 95

List of Figures

Figure 1: Opportunity Analysis – Clinical and Commercial Impact 50
Figure 2: Outline of Push and Pull Incentives for Antibiotic Development 59
Figure 3: Regulatory Trends in Antibiotic Drug Development 74
Figure 4: Traditional and Partnership Business Models in Antibiotic R&D 87

Read the full report:
PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria
http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmafocus_market_access_strategies_antibiotics_targeting_multidrug_resistant_gram_negative_bacteria.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.